Bristol-Myers Squibb raised its 2025 EPS outlook after a Q1 beat, with shares trading far below historical P/E levels. Find ...

Bristol Myers Squibb Co. raised its sales and profit forecasts for the year on better-than-expected sales of older drugs and ...

Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to loss of $4.40 per share a year ago. These ...

By Jonathan Stempel NEW YORK (Reuters) -Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an ...

Ascent Industries (ACNT) announced the successful closing of the previously announced sale of substantially all of the assets of Bristol Metals ...

--(BUSINESS WIRE)-- Ascent Industries Co. (Nasdaq ... a definitive agreement to sell substantially all of the assets of Bristol Metals, LLC (“BRISMET”) to Ta Chen International, Inc.